Overall, this study represents a strategically adaptive platform to define optimal combination regimens of ATR inhibition and establish biologically active doses across diverse therapeutic contexts, ultimately informing subsequent biomarker-guided trials in molecularly defined cancer populations. This evidence concerns the gene ATR and cancer.